586-16-3

Usage

InChI:InChI=1/C9H9FO2/c1-2-8(11)6-3-4-9(12)7(10)5-6/h3-5,12H,2H2,1H3

Upstream product

• 586-22-1 1-(3-fluoro-4-methoxyphenyl)propan-1-one 
• 367-12-4 2-fluorophenol 
• 79-03-8 propionyl chloride 
• 331-62-4 3-fluoro-4-methoxybenzonitrile 
• 2357-52-0 3-fluoro-4-methoxyphenyl bromide 
• 92821-96-0 propionic acid-(2-fluorophenyl) ester 
• 2105-94-4 4-bromo-2-fluorophenol 
• 104863-65-2 N-methyl-N-methoxypropionamide 
• 321-28-8 1-fluoro-2-methoxybenzene 

Downstream Products

• 350-14-1 1-(3-bromo-5-fluoro-4-hydroxy-phenyl)-propan-1-one 
• 390-26-1 2-(3-fluoro-4-hydroxy-phenyl)-3-methyl-quinoline-4-carboxylic acid 
• 86615-79-4 C₉H₈ClFO₂ 
• 577-87-7 2-fluoro-4-(3-methyl-[2]quinolyl)-phenol 
• 343-05-5 2-fluoro-4-(3-methyl-indol-2-yl)-phenol 

Relevant academic research and scientific papers

NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS

The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.

ALKYLIDENE TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS

The invention relates to alkylidene tetrahydronaphthalene derivatives of general formula (I), to methods for their production and to their use as anti-inflammatory agents.

COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS

This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.

Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives

PCT No. PCT/IB95/00380 Sec. 371 Date Feb. 13, 1996 Sec. 102(e) Date Feb. 13, 1996 PCT Filed May 18, 1995 PCT Pub. No. WO96/06081 PCT Pub. Date Feb. 29, 1996This invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein: (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7 and R5 is methyl or ethyl; or (b) R2 and R5 are taken together, forming a chroman-4-ol ring, and R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; and R6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo(3.2.1)octanyl derivative; provided that (a) when R2 and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and (b) when R2 and R5 are taken together, at least one of R1, R3 and R4 is not hydrogen; pharmaceutical compositions thereof; and methods of treating mammals suffering from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised with a compound of formula (I) hereinabove or a pharmaceutically acceptable salt thereof.